Apolipoprotein(a) in the carotid artery plaque: Evidence for proteolytic and pro-inflammatory modifications

Vascular Disease Prevention

Volumn 5, Issue 1, 2008, Pages 1-8

  Joy, Stephen T ^a   Patel, Priyesh N ^a   Pfaffinger, Ditta ^a   Edelstein, Celina ^a   Scanu, Angelo M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apolipoprotein(a); Carotid artery plaque; Inflammation; Kringle V; Oxidized phospholipids

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; FIBRONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PHOSPHATIDYLCHOLINE; POLYCLONAL ANTIBODY;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LASER MICRODISSECTION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; SURGICAL TECHNIQUE; WESTERN BLOTTING;

EID: 40549103450     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727008783503116     Document Type: Article

References (31)

1. Scanu AM. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr Atheroscler Rep 2003; 5: 106-13.
2. Berglund L, Ramakrishnan R. An elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004; 24: 2219-26.
3. Edelstein C, Italia JA, Klezovitch O, Scanu AM. Functional and metabolic differences between elastase-generated fragments of human lipoprotein(a) and apolipoprotein(a). J Lipid Res 1996; 37: 1786-801.
4. Edelstein C, Italia JI, Scanu AM. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase: generation of miniLp(a) particles and apo(a) fragments. J Biol Chem 1997; 272: 11079-87.
5. Edelstein C, Shapiro SD, Klezovitch O, Scanu AM. Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein(a) biology. J Biol Chem 1999; 274: 10019-23.
6. Edelstein C, Youssef M, Scanu AM. Elements in the C terminus of apolipoprotein(a) responsible for the binding to the tenth type III module of human fibronectin. J Lipid Res 2005; 46: 2673-80.
7. Scanu AM, Edelstein C, Klezovitch O. Dominant role of the C-terminal domain of apolipoprotein(a) to the protein core of proteoglycans and other members of the extracellular matrix. Trends Cardiovasc Med 2000; 9: 196-200.
8. Edelstein C, Pfaffinger D, Hinman J, et al. Lysine- phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003; 26: 52841-47.
9. Klezovitch O, Edelstein C, Scanu AM. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a): evidence for a critical involvement of elements of its C-terminal domain. J Biol Chem 2001; 276: 46864-69.
10. Williams KJ, Tabas I. The response-to retention- hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-61.
11. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidiol 1998; 9: 471-74.
12. Formato M, Farina M, Spirito R, et al. Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Atheroscler Thromb Vasc Biol 2004; 24: 129-35.
13. Fless GM, Snyder ML, Scanu AM. Enzyme-linked immunoassay for Lp(a). J Lipid Res 1989; 30: 651-62.
14. Jerne NK, Roland J, Cazenave P-A. Recurrent idiotypes and internal images. EMBO J 1982; 1: 243-47.
15. Shaw PX, Hörkkö S, Chang-Kyung M, et al. Natural antibodies with theT15 idiotype may act in atherosclerosis, apopotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731-40.
16. National Heart Lung, and Blood Institute. Third Report of the NationalCholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary: National Institutes of Health, Bethesda, MD; 2001. Report No.: Publication 01-3670.
17. Briles DE, Forman C, Hudak S, Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med 1982; 156: 1177-85.
18. Kearney JF, Barletta R, Quan ZS, Quintans J. Monoclonal vs. heterogeneous anti-H-8 antibodies in the analysis of the antiphosphorylcholine response in BALB/c mice. Eur J Immunol 1981; 11: 877-83.
19. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndrome. J Am Coll Cardiol 2003; 41: 360-70.
20. Scanu AM. Lp(a). In Fuster V, Topol E, Nabel E, Eds. Atherothrombosis and Coronary Heart Disease. Philadelphia: Lippincott Williams and Wilkins; 2005; pp. 123-28.
21. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006; 69: 625-35.
22. Scanu AM, Chellamma S. Cleavage of human apolipoprotein(a) coated on the surface of constituents of the vascular extracellular matrix by pancreatic elastase and metalloproteinase-12. Different partitions between cleaved N-terminal and C-terminal domains. Vasc Dis Prev 2004; 1: 59-63.
23. Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol 2006; 98: 9-17.
24. Kostner KM, Huber K, Stefenelli T, Rinner H, Maurer G. Urinary apo(a) discriminates coronary rtery disease patients from controls. Atherosclerosis 1997; 129: 103-10.
25. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-73.
26. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids. Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353: 46-57.
27. Scanu AM. Lp(a) Lipoprotein - Coping with heterogeneity. N Engl J Med 2003; 349: 2089-90.
28. Paraskevas KO, Hamilton G, Mikhailidis DP. Statins: An essential component in the management of carotid artery disease. J Vasc Surg 2007; 46: 373-86.
29. Discepolo W, Wun T, Berglund L. Lipoprotein(a) and Thrombocytes: Potential mechanisms underlying cardiovascular risk. Pathophysiol Haemost Thromb 2006; 35: 314-21.
30. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic disease. Clin Chem 2002; 48: 1454-59.
31. Edelstein C, Mandala M, Pfaffinger D, Scanu AM. Determinants of lipoprotein(a) assembly: A study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry 1995; 34: 16483-92.